Validation of the Intestinal Part of the Prostate Cancer Questionnaire "QUFW94": Psychometric Properties, Responsiveness, and Content Validity

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 3, 2010, Pages 793-804

  Reidunsdatter, Randi J ^a   Lund, Jo Åsmund ^b,c   Fransson, Per ^d   Widmark, Anders ^d   Fosså, Sophie D ^e   Kaasa, Stein ^b,c  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

HRQOL; Intestinal; Module; Prostate; Radiotherapy

Indexed keywords

DAILY ACTIVITY; EXPLORATORY FACTOR ANALYSIS; FACTOR ANALYSIS; HEALTH-RELATED QUALITY OF LIVES; INTERNAL CONSISTENCY; POST TREATMENT; PROSTATE CANCERS; PROSTATE RADIOTHERAPY; PSYCHOMETRIC PROPERTIES; SELF-ASSESSMENT;

RADIOTHERAPY;

ADULT; AGED; ARTICLE; CONTENT VALIDITY; CRONBACH ALPHA COEFFICIENT; DAILY LIFE ACTIVITY; DEFECATION; FACTORIAL ANALYSIS; FECES INCONTINENCE; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; QUFW94 QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SYMPTOM; VALIDATION STUDY;

FECAL INCONTINENCE; FECES; GASES; HEALTH STATUS; HUMANS; MALE; PROSTATIC NEOPLASMS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY; RECTAL DISEASES; REPRODUCIBILITY OF RESULTS;

EID: 77952560706     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.05.057     Document Type: Article

References (39)

1. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
2. Cella D.F., Tulsky D.S., Gray G., et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11 (1993) 570-579
3. Sprangers M.A., Cull A., Bjordal K., et al. The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: Guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life. Qual Life Res 2 (1993) 287-295
4. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
5. Millikan R., and Logothetis C. Update of the NCCN guidelines for treatment of prostate cancer. Oncology (Huntingt) 11 (1997) 180-193
6. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292 (2004) 821-827
7. See W.A., and Tyrrell C.J. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol 132 Suppl 1 (2006) S7-16
8. Widmark A., Klepp O., Solberg A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised Phase III trial. Lancet 373 (2009) 301-308
9. Lee W.R., Hall M.C., McQuellon R.P., et al. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 614-623
10. Esper P., Mo F., Chodak G., et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 50 (1997) 920-928
11. Borghede G., and Sullivan M. Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30. Qual Life Res 5 (1996) 212-222
12. Dale W., Campbell T., Ignacio L., et al. Self-assessed health-related quality of life in men being treated for prostate cancer with radiotherapy: Instrument validation and its relation to patient-assessed bother of symptoms. Urology 53 (1999) 359-366
13. Litwin M.S., Hays R.D., Fink A., et al. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 36 (1998) 1002-1012
14. Wei J.T., Dunn R.L., Litwin M.S., et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56 (2000) 899-905
15. Widmark A., Fransson P., and Tavelin B. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 74 (1994) 2520-2532
16. Fransson P., Tavelin B., and Widmark A. Reliability and responsiveness of a prostate cancer questionnaire for radiotherapy-induced side effects. Support Care Cancer 9 (2001) 187-198
17. Fransson P., and Widmark A. Late side effects unchanged 4-8 years after radiotherapy for prostate carcinoma: A comparison with age-matched controls. Cancer 85 (1999) 678-688
18. Fransson P., Damber J.E., Tomic R., et al. Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma. Cancer 92 (2001) 3111-3119
19. Fransson P., Lund J.A., Damber J.E., et al. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, Phase III trial. Lancet Oncol 10 (2009) 370-380
20. Fransson P., Bergstrom P., Lofroth P.O., and Widmark A. Five-year prospective patient evaluation of bladder and bowel symptoms after dose-escalated radiotherapy for prostate cancer with the BeamCath technique. Int J Radiat Oncol Biol Phys 66 (2006) 430-438
21. Fransson P., and Widmark A. 15-year prospective follow-up of patient-reported outcomes of late bowel toxicity after external beam radiotherapy for localized prostate cancer. A comparison with age-matched controls. Acta Oncol 46 (2007) 517-524
22. Ataman F., Zurlo A., Artignan X., et al. Late toxicity following conventional radiotherapy for prostate cancer: Analysis of the EORTC trial 22863. Eur J Cancer 40 (2004) 1674-1681
23. Bolla M., Van P.H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
24. Dearnaley D.P., Sydes M.R., Langley R.E., et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol 83 (2007) 31-41
25. Peeters S.T., Heemsbergen W.D., van Putten W.L., et al. Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (2005) 1019-1034
26. Wiegel T., Bottke D., Steiner U., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27 (2009) 2924-2930
27. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
28. Fayers P.M. Mach, Machin D. Factor analysis. Quality of life, assessment, analysis and interpretation (2000), John Wiley, New York p. 91-116
29. Osoba D., Rodrigues G., Myles J., et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16 (1998) 139-144
30. Rodrigues G., Bauman G., Lock M., et al. Psychometric properties of a prostate cancer radiation late toxicity questionnaire. Health Qual Life Outcomes 5 (2007) 29
31. van Tol-Geerdink J.J., Leer J.W., van Lin E.N., et al. Offering a treatment choice in the irradiation of prostate cancer leads to better informed and more active patients, without harm to well-being. Int J Radiat Oncol Biol Phys 70 (2008) 442-448
32. Fayers P.M., and Machin D. Principles of measurement scales. Quality of life, assessment, analysis and interpretation (2000), John Wiley, New York p. 28-42
33. Borghede G., Karlsson J., and Sullivan M. Quality of life in patients with prostatic cancer: results from a Swedish population study. J Urol 158 (1997) 1477-1485
34. Jackson A. Partial irradiation of the rectum. Semin Radiat Oncol 11 (2001) 215-223
35. Yeoh E.E., Botten R., Russo A., et al. Chronic effects of therapeutic irradiation for localized prostatic carcinoma on anorectal function. Int J Radiat Oncol Biol Phys 47 (2000) 915-924
36. Holzbeierlein J.M., Castle E., and Thrasher J.B. Complications of androgen deprivation therapy: prevention and treatment. Oncology 18 (2004) 303-309 Williston Park
37. Lips I., Dehnad H., Kruger A.B., et al. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys 69 (2007) 656-661
38. Zelefsky M.J., Levin E.J., Hunt M., Yamada Y., Shippy A.M., Jackson A., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 1124-1129
39. Sprangers M.A., Cull A., Groenvold M., et al. The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: An update and overview. EORTC Quality of Life Study Group. Qual Life Res 7 (1998) 291-300